These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 29987478)

  • 1. Cancer immune therapy for myeloid malignancies: present and future.
    Holmström MO; Hasselbalch HC
    Semin Immunopathol; 2019 Jan; 41(1):97-109. PubMed ID: 29987478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?
    Liu Y; Bewersdorf JP; Stahl M; Zeidan AM
    Blood Rev; 2019 Mar; 34():67-83. PubMed ID: 30553527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myeloid-derived suppressor cells: Implication in myeloid malignancies and immunotherapy.
    Kapor S; Radojković M; Santibanez JF
    Acta Histochem; 2024 Oct; 126(5-7):152183. PubMed ID: 39029317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The emerging role of immune checkpoint based approaches in AML and MDS.
    Boddu P; Kantarjian H; Garcia-Manero G; Allison J; Sharma P; Daver N
    Leuk Lymphoma; 2018 Apr; 59(4):790-802. PubMed ID: 28679300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled.
    Bewersdorf JP; Stahl M; Zeidan AM
    Expert Rev Anticancer Ther; 2019 May; 19(5):393-404. PubMed ID: 30887841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
    Orazi A
    Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BITES and CARS and checkpoints, oh my! Updates regarding immunotherapy for myeloid malignancies from the 2018 annual ASH meeting.
    Przespolewski AC; Griffiths EA
    Blood Rev; 2020 Sep; 43():100654. PubMed ID: 32029263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune-dysregulation harnessing in myeloid neoplasms.
    Sharifi MJ; Xu L; Nasiri N; Ashja-Arvan M; Soleimanzadeh H; Ganjalikhani-Hakemi M
    Cancer Med; 2024 Sep; 13(17):e70152. PubMed ID: 39254117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-1 signaling and inhibition in AML and MDS.
    Haroun F; Solola SA; Nassereddine S; Tabbara I
    Ann Hematol; 2017 Sep; 96(9):1441-1448. PubMed ID: 28643044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Approaches to Acute Myeloid Leukemia Immunotherapy.
    Beyar-Katz O; Gill S
    Clin Cancer Res; 2018 Nov; 24(22):5502-5515. PubMed ID: 29903894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-intensity allogeneic hematopoietic stem cell transplantation for myeloid malignancies: separating graft-versus-leukemia effects from graft-versus-host disease.
    Burroughs L; Storb R
    Curr Opin Hematol; 2005 Jan; 12(1):45-54. PubMed ID: 15604891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells.
    Grabrucker C; Liepert A; Dreyig J; Kremser A; Kroell T; Freudenreich M; Schmid C; Schweiger C; Tischer J; Kolb HJ; Schmetzer H
    J Immunother; 2010 Jun; 33(5):523-37. PubMed ID: 20463595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells.
    Carlsten M; Järås M
    Front Immunol; 2019; 10():2357. PubMed ID: 31681270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloid malignancies: myelodysplastic syndromes, myeloproliferative disorders, and acute myeloid leukemia.
    Wood BL
    Clin Lab Med; 2007 Sep; 27(3):551-75, vii. PubMed ID: 17658407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Germline mutations in the bone marrow microenvironment and dysregulated hematopoiesis.
    Miller LH; Qu CK; Pauly M
    Exp Hematol; 2018 Oct; 66():17-26. PubMed ID: 30076950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is survival in myeloid malignancies really improving? A retrospective 15-year population-based study.
    Osca-Gelis G; Puig-Vives M; Saez M; Gallardo D; Lloveras N; Guàrdia R; Marcos-Gragera R
    Leuk Lymphoma; 2015 Apr; 56(4):896-902. PubMed ID: 25058372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoint pathways: perspectives on myeloid malignancies.
    Rivera GA; Saramipoor Behbahan I; Greenberg PL
    Leuk Lymphoma; 2016 May; 57(5):995-1001. PubMed ID: 26916355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer vaccines for patients with acute myeloid leukemia--definition of leukemia-associated antigens and current clinical protocols targeting these antigens.
    Greiner J; Döhner H; Schmitt M
    Haematologica; 2006 Dec; 91(12):1653-61. PubMed ID: 17145602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy in Myeloproliferative Diseases.
    Braun LM; Zeiser R
    Cells; 2020 Jun; 9(6):. PubMed ID: 32604862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccine and Cell-based Therapeutic Approaches in Acute Myeloid Leukemia.
    Agrawal V; Gbolahan OB; Stahl M; Zeidan AM; Zaid MA; Farag SS; Konig H
    Curr Cancer Drug Targets; 2020; 20(7):473-489. PubMed ID: 32357813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.